Who Paid My Doc
Amy Young
Molecular Genetic Pathology Aurora, CO Medical Doctor
NPI 1952808388 CMS profile 11453479
12605 E 16Th Ave, Aurora, CO 80045
General payments
$135
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amy Young of Aurora, CO is reported in the CMS Open Payments database as having received $135 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $135 | 1 |
Beside peers
- Amy Young
- Molecular Genetic Pathology median
- Middle half of Molecular Genetic Pathology
- National median
In program year 2025, general payments to Amy Young were reported at $135. Among 27 Molecular Genetic Pathology profiles paid that year, the median was $225 and the middle half received between $91 and $3,596.
Show as a table
| Year | Amy Young | Molecular Genetic Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $131 | $38–$1,524 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $900 | $25–$1,899 | $132 |
| 2022 | $0 | $136 | $28–$4,738 | $149 |
| 2023 | $0 | $139 | $48–$3,150 | $160 |
| 2024 | $0 | $1,077 | $71–$2,833 | $164 |
| 2025 | $135 | $225 | $91–$3,596 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$31,678
Medicare patients
1,054
Services billed
1,974
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 55% | |
| Chronic kidney disease | 35% | |
| Ischemic heart disease | 30% | |
| Cancer | 28% | |
| Osteoporosis | 26% | |
| Diabetes | 25% | |
| Depression | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Molecular Genetic Pathology in Colorado
Related records
Molecular Genetic Pathology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Molecular Genetic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.